Heterogenetiy of Monocytes and Echocardiography among allograft recipients in nephrology

Inclusion Criteria:

Subjects after allogenic renal transplantation (time since transplantation ≥ 12 months)

Exclusion Criteria:

Acute infectious disease
Active malignant disease
Acute renal injury

Baseline Parameters:

Traditional cardiovascular risk factors
Parameters of calcium-phosphate metabolism
Echocardiography
Ultrasound renal resistive indices
Cell counts of monocyte subsets

Number of Participants:

222 Participants scheduled to be included (recruitment ongoing)

Combined primary cardiovascular outcome:

Any cardiovascular event (acute myocardial infarction; surgical or interventional coronary / cerebrovascular / peripheral-arterial revascularization; stroke [symptoms ≥ 24 hours]; amputation above the ankle; death)

Combined primary renal outcome:

Reduction of eGFR ≤50% baseline, ESRD (renal replacement therapy for ≥ 3 months), death

Secondary cardiovascular outcome:

Acute myocardial infarction, ischemic stroke (symptoms ≥ 24 hours), cardiovascular death

Secondary renal outcome:

Reduction of eGFR ≤50% baseline, ESRD (renal replacement therapy for ≥ 3 months)

Pulications:

Rogacev KS¹, Zawada AM¹, Hundsdorfer J, Achenbach M, Held G, Fliser D, Heine GH.

Immunosuppression and monocyte subsets.

Nephrol Dial Transplant 2015 Jan;30(1):143-53. Abstract

Medical Theses:

Johanna Hundsdorfer

Einfluss immunsuppressiver Medikamente auf die Monozytenheterogenität bei nierentransplantierten Patienten

Lucie Bauer (ongoing)